Furthermore, immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and its ligand (PD-L1) are commonly used to treat advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [20]. Here, PDCD1 is linked to non-small cell lung carcinoma.